Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole
for treatment of estrogen receptor-positive rare ovarian cancer.